Xenoport shares sink on disappointing clinical trial(0)
Shares of Xenoport hit a 52-week low Monday, diving $2.62, or 15 percent, to close at $14.76 after the Santa Clara drug maker and its partner, GlaxoSmithKline, reported that a clinical trial of its treatment for neuropathic pain associated with diabetic peripheral neuropathy in adults “did not demonstrate a statistically significant improvement” when compared to a placebo.
In November, Xenoport’s shares got similarly slammed when Read the rest of this entry »
Subscribe via RSS all feeds